Quick Listen: Scrip’s Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: Pfizer buys into hematology; changes at the top at J&J; the outlook for solid tumor drug approvals; mRNA vaccine progress in India; and a look at diversity in clinical trials.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 27 August 2021, including: Pfizer Inc. buys into hematology; changes at the top at Johnson & Johnson; the outlook for solid tumor drug approvals; mRNA vaccine progress in India; and a look at diversity in clinical trials.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Pfizer To Buy Trillium For $2.26bn In A Hematology Pipeline Play" - Scrip, 23 Aug, 2021.)
(Also see "J&J CEO Gorsky Handing Over The Reins To Vice Chairman Duato" - Scrip, 20 Aug, 2021.)
(Also see "Eight Oncology Drug Launches Expected In 2022 – Solid Tumors" - Scrip, 25 Aug, 2021.)
(Also see "Indian Biotech In mRNA Push As COVID-19 Vaccine Moves To Phase II" - Scrip, 26 Aug, 2021.)
(Also see "Breast Cancer Trial Enrollment Illustrates Diversity Challenge" - Scrip, 19 Aug, 2021.)